ID | 1281 |
Name of the vaccine | HEXAVAC |
Microbe | Bacteria |
Disease name | Pertussis (Whooping Cough) |
Name of bacteria | Bordetella pertussis |
Type of vaccine | Combination |
Nucleic acid content | DNA |
Age | 8 to 15 weeks |
Description of the vaccine | DTPa-HBV-IPV-Hib vaccine. |
Name of the manufacturer | GlaxoSmithKline |
Name of the manufacturing country | Finland, Italy, Sweden |
Year of manufacture | 2005 |
Clinical Phase status | Clinical - Phase 4 |
Bacterial strain | Gram-negative coccobacillus. |
Efficacy | NA |
Vaccine formulation | Suspension for injection |
Dosage | Three doses at 3, 5 and 11-12 months. |
Mechanism of action | NA |
Route of administration | Intramuscular |
Indications | NA |
Export | Marketing-authorisation holder : Sanofi Pasteur MSD, SNC |
Approval | NA |
Adjuvant | NA |
Repurposing | For diphtheria, tetanus, hepatitis B, Haemophilus influenzae type b and poliomyelitis. |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Combination (3 doses) |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NCT01457547 |
Reference | https://www.ema.europa.eu/en/medicines/human/EPAR/hexavac |
Other name | NA |
Additional Links | NA
|